The 2023 RNA Landscape Review
An analysis of the entire clinical and therapeutic landscape by phase distribution, disease indication, trial status and more, as well as an overview of the commercial landscape including deal type, company location and funding and a look towards the future of the space.
About the report
The analysis includes:
-
- The Drug and Trial Landscape– An analysis of all 3740+ drugs and 1860+ trials on Beacon RNA by modality, trial status, disease indication and more, providing a comprehensive overview of the entire RNA landscape.
- The Deals and Companies Landscape & Regulatory –Insight into the commercial landscape, using the new Deals and Companies dataset, including deal types and company location, and a look at the regulatory updates and future of the space based on data availability.
You may also be interested in...
Webinar – Unlocking the Future of RNA Therapeutics: Delivery System Evolution, Preclinical Insights, and Market Impact
H1 2024 Immune Tolerance Landscape Review
H1 2024 RNA Landscape Review
H1 2024 Gene Therapy Landscape Review
H1 2024 Cell Therapy Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
